PHASE 3 STUDY EVALUATING GENE THERAPY BY TRANSPLANTATION OF AUTOLOGOUS CD34+ STEM CELLS TRANSDUCED EX VIVO WITH THE LENTIGLOBIN BB305 LENTIVIRAL VECTOR IN SUBJECTS WITH SEVERE SICKLE CELL DISEASE
Clinical Trial Grant
Administered By
Pediatrics, Transplant and Cellular Therapy
Awarded By
Bluebird Bio
Start Date
April 17, 2020
End Date
March 29, 2026
Administered By
Pediatrics, Transplant and Cellular Therapy
Awarded By
Bluebird Bio
Start Date
April 17, 2020
End Date
March 29, 2026